Stock Taper
SCREENER COMPARE ANY 2 STOCKS
GLMD
GALMED PHARMACEUTICALS LTD.
NASDAQ
$4.17
▼ DOWN 3.27% (-0.14)

KEY STATISTICS

Market Cap$4.30 M
52w High$13.20
52w Low$3.29
Dividend Yield—
Frequency—
P/E-0.99
Volume4.70K
Shares Out.1.03M

COMPANY

LEADERSHIP

Allen Baharaff
CHIEF EXECUTIVE
Allen Baharaff

ABOUT

SECTOR
Healthcare
WENT PUBLIC
March 12, 2014
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
6

UPCOMING EARNINGS

DateNov 25, 2026
DayWednesday
Rev. Est.—
NOV
25
WED

SPLIT RECORD

DATETYPERATIO
2026-08-19Reverse1:8
2024-08-30Reverse1:12
2023-05-15Reverse1:15

PRICE

$4.17 ▼ DOWN 3.27% (−$0.14)
OVERLAYS
$4.05$4.209:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM4.17

About Galmed Pharmaceuticals Ltd.

https://galmedpharma.com ↗

Galmed Pharmaceuticals Ltd., an Israeli clinical-stage biopharma, develops liver disease therapeutics like Aramchol (in Phase III for NASH) and Amilo-5MER, collaborating globally for research, development, and commercialization.

INDUSTRY

Biotechnology

A PRODUCT GALMED PHARMACEUTICALS LTD. IS KNOWN FOR

Aramchol Meglumine
Aramchol Meglumine

Aramchol Meglumine is Galmed's lead oral drug candidate for NASH and liver fibrosis, with improved solubility, currently in Phase 3 trials, targeting steatosis, inflammation, and fibrosis.

COMPETITORS

COMPETITOR
MDGL COMPARE
VKTX COMPARE

INSTITUTIONAL OWNERSHIP

SHARES OWNED
2.47%
HOLDERS
2
TOP 2 OF 2 · RANKED BY POSITION SIZE
Delek Group, Ltd.
24.6K sh · $176K
Edmond De Rothschild (Europe)
916 sh · $4K

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book5
Overall Score2

SECTORS PEERS

PEERPRICE
VRAX$2.82COMPARE
CMMB$2.71COMPARE
BIVI$2.16COMPARE
MLEC$6.80COMPARE
INM$1.38COMPARE
ELAB$5.31COMPARE
BDRX$0.87COMPARE
NKGN$0.00COMPARE